Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
Bayer Wins Major U.S. Supreme Court Roundup Lawsuit, Shares Surge 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
Samsung, SK Hynix to Unveil Record AI and Semiconductor Investment Plans Worth Over $646 Billion 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
BRIDGEWATER, N.J., May 08, 2017 -- Valeritas Holdings, Inc. (NASDAQ:VLRX) announced today that the Company is scheduled to present at the 18th Annual B. Riley Co. Investor Conference.
| Event: | 18th Annual B. Riley Co. Investor Conference |
| Format: | Presentation and One-on-One Meetings |
| Date: | Wednesday, May 24, 2017 |
| Time: | 1:00pm PT |
| Location: | Santa Monica, CA |
An audio webcast of the Company’s presentation will be available by visiting the investor relations section of the Valeritas website at www.valeritas.com. Replays of the presentation will be available for 90 days.
About Valeritas Holdings, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery device for patients with type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides discreet on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit www.valeritas.com.
Investor Contacts: Nick Laudico / Robert Flamm, Ph.D. The Ruth Group 646-536-7030 / 7017 [email protected] Or The Del Mar Consulting Group, Inc. Robert B. Prag, President 858-794-9500 [email protected] Media Contact: Kirsten Thomas The Ruth Group 508-280-6592 [email protected]
